A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Recruiting

Phase 2

Gene TherapyA Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Sponsor:

Janssen Research & Development, LLC

Code:

NCT06646289

Conditions

X-Linked Retinitis Pigmentosa

Eligibility Criteria

Sex: Male

Age: 5+

Healthy Volunteers: Not accepted

Interventions

AAV5-hRKp.RPGR

No intervention (Follow-Up assessment)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-03. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-09-22.